|
- 2018
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorderDOI: 10.2147/PGPM.S160763 Keywords: pharmacogenetics, SSRIs, fluvoxamine, biotransformation, personalized medicine, CYP2D6, depressive disorders, alcohol addiction Abstract: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotransformation of fluvoxamine. Meanwhile, the genes encoding these isoenzymes have a high level of polymorphism, which may affect the protein synthesis
|